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Diabetic nephropathy is characterized by excessive
extracellular matrix accumulation resulting in renal scarring
and end-stage renal disease. Previous studies have suggested
that transglutaminase type 2, by formation of its protein
crosslink product e-(c-glutamyl)lysine, alters extracellular
matrix homeostasis, causing basement membrane thickening
and expansion of the mesangium and interstitium. To
determine whether transglutaminase inhibition can slow the
progression of chronic experimental diabetic nephropathy
over an extended treatment period, the inhibitor NTU281
was given to uninephrectomized streptozotocin-induced
diabetic rats for up to 8 months. Effective transglutaminase
inhibition significantly reversed the increased serum
creatinine and albuminuria in the diabetic rats. These
improvements were accompanied by a fivefold decrease
in glomerulosclerosis and a sixfold reduction in
tubulointerstitial scarring. This was associated with
reductions in collagen IV accumulation by 4 months, along
with reductions in collagens I and III by 8 months. This
inhibition also decreased the number of myofibroblasts,
suggesting that tissue transglutaminase may play a role in
myofibroblast transformation. Our study suggests that
transglutaminase inhibition ameliorates the progression of
experimental diabetic nephropathy and can be considered
for clinical application.
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Diabetic nephropathy (DN) is the most common cause of
end-stage renal disease1,2 accounting for 50% of cases
requiring renal replacement therapy in the United States.3
This is due to the increasing prevalence of type 2 diabetes and
the reduced mortality of DN patients resulting from better
management. Diabetic patients now live longer and patients
with diabetic end-stage renal disease are now being accepted
for treatment in dialysis programs where formerly they might
have been excluded.
Clinically, the progression of DN is accompanied by the
development of proteinuria and early glomerular hyperfiltra-
tion followed by a decline of glomerular filtration rate.
Morphologically, it is characterized by excessive renal
extracellular matrix (ECM) accumulation in the glomeruli
and tubulointerstitial space, causing glomerulosclerosis and
tubulointerstitial fibrosis. This ultimately leads to end-stage
renal disease.
Transglutaminase type 2 (TG2) is a calcium-dependent
enzyme that catalyzes an acyl-transfer reaction (EC 2.3.2.13)
between the g-carboxamide group of peptide-bound gluta-
mine and the e-amino group of peptide-bound lysine. This
leads to the formation of a stable and proteolytic-resistant
e-(g-glutamyl)lysine dipeptide bond, resulting in intra- or
intermolecular crosslinks in protein. A number of extracel-
lular proteins including fibronectin,4 collagen,5 fibrinogen,6
osteopontin,7 laminin, and nidogen8 are TG2 substrates.
When TG2 is released from the cell, the high extracellular
Ca2þ and low GTP (which modulates Ca2þ activation of the
enzyme) activates the enzyme, enabling crosslinking of these
ECM proteins at the cell surface and in the surrounding
matrix. Crosslinking of collagen by TG2 has been associated
with stabilization of the collagen fibril independently of lysyl
oxidase,5 accelerated ECM deposition,9 reduced proteolytic
breakdown of the ECM,10 and ultimately lower ECM
turnover.11 Thus, TG2 action shifts the ECM deposition–
degradation balance toward accumulation12 and has subse-
quently been linked to a range of fibrogenic conditions.
A role for TG2 in the pathogenesis of DN has been
reported in both the streptozotocin (STZ)-induced model of
type 1 diabetes13 and human diabetic kidney disease,14 with
increased TG2-mediated e-(g-glutamyl)lysine crosslink
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formation in diabetic kidneys tightly associated with both
glomerular and tubulointerstitial ECM expansion. Currently,
there remains no viable mechanism for interfering with this
ECM buildup. Subsequently, the development of therapeutic
approaches directly targeting this process may provide an
effective approach to the prevention of DN as well as
numerous other fibrotic conditions. The inhibition of TG
activity in proximal tubular epithelial cells in culture has
already been shown to reduce glucose-induced ECM
accumulation,15 providing strong support for the in vivo
application of such compounds in the treatment for DN.
Therefore, in this study, the TG site-directed irreversible
inhibitor N-benzyloxycarbonyl-L-phenylalanyl-6-dimethyl-
sulfonium-5-oxo-L-norleucine (NTU281) has been applied
by direct intrarenal infusion into the kidneys of rats receiving
STZ injection and by uninephrectomy over an 8-month
treatment period. NTU281 is a benzyloxycarbonyl phenyla-
lanyl analog containing a dimethylsulfonium group that
binds the cysteine residue in the active site of TG to instigate
an acetonylation reaction leading to permanent noncompe-
titive inhibition of the enzyme.16 Whereas the STZ model is
not a direct representative of DN in humans as it lacks the
characteristic histological lesions, it is a useful surrogate for
the impact of sustained hyperglycemia on changes in ECM
turnover in the kidney. Uninephrectomy has been used to
accelerate diabetic kidney changes.17,18 We report that TG
inhibition can preserve kidney function, reduce albuminuria,
and ameliorate the progression of the histological changes
associated with the formation of scar tissue in DN.
RESULTS
Verification of drug delivery
To ascertain if intrarenal cannulation was achieving uniform
drug delivery throughout the kidney, we prepared a dansyl-
labeled version of NTU281. Using a kidney that was
cannulated 28 days previously (to allow the fibrous coat
around the cannula to develop) and had received phosphate-
buffered saline from implant, we infused 50mM dansyl-
labeled NTU281 for 24 h. Cryostat sections viewed under a
fluorescent microscope showed a uniform distribution of
dansyl-NTU281 in both the longitudinal and the transverse
planes in comparison with the contralateral kidney where no
fluorescence was visible (Figure 1a). Import of images into
multianalyst image analysis software allowed densitometric
profile assessment of the fluorescence, which confirmed equal
distribution in both planes (Figure 1b).
Experimental groups
Four experimental groups were used. Normal, uninephrec-
tomy (UNx), UNxþ Streptozotocin (STZ) (referred to
as diabetic or DM), and UNxþ STZþTransglutaminase
inhibitor NTU281 (referred to as diabetic treated).
General observations
Calculation of osmotic pump delivery rates from residual
pump volumes showed a consistent drug delivery throughout
the treatment period (Figure 2a). Examination of cannulas at
termination indicated that all had remained in situ and there
was no evidence of cannula leakage.
Compared with normal and UNx animals, both diabetic
groups (that is, treated and untreated with NTU281)
had higher levels of blood glucose throughout the experi-
mental period (Figure 2c) and within the 10–25mmol/l target
range using a comparable insulin dose (Figure 2b), thus
showing an equal metabolic burden in treated and untreated
rats.
In hyperglycemic animals by 8 months post-STZ, body
weight gain was approximately twofold lower (Figure 2d)
than that in normal rats, reaching 355±12.8 and 377±14.3 g
in diabetic and NTU281-treated diabetic rats, respectively,
compared with 546±22.6 g in normal (Table 1).
Kidney weight following UNx was greater than that in
normal, but only significantly at 1 month post-STZ (Table 1).
Imposing hyperglycemia caused a marked increase in kidney
weight, being more than threefold greater by 8 months;
however, TG inhibition reduced increased kidney weight by
42% at this point (Table 1).
Although blood pressure was raised in hyperglycemic
animals, there was no significant difference in systolic blood
pressure between the four groups throughout the study (not
shown).
Effectiveness of TG inhibition
TG in situ activity assays showed a sixfold increase
in extracellular TG activity in the untreated diabetic animals
by 8 months (Figure 3i). Increased extracellular TG activity
was present both in the glomeruli and in the tubulointer-
stitial compartments (Figure 3ii). In comparison, the
extracellular TG activity in the NTU281-treated diabetic
rats remained similar to that in both normal and UNx
controls throughout (Figure 3i). In agreement with less
extracellular TG activity in treated animals were lower levels
of catalyzed e-(g-glutamyl)lysine crosslinking (Po0.05),
which were unaltered compared with the normal and UNx
controls throughout the experimental period (Figure 3iii),
showing continuous effective TG inhibition.
Kidney function and albuminuria
Kidney function was assessed using serum creatinine. In
untreated diabetic animals, serum creatinine rose throughout
the experimental period, with more than a 3.5-fold increase
by 8 months compared with that in controls (Figure 2e).
Although a small increase in serum creatinine (Po0.05) was
detected in the NTU281-treated diabetic rats by 8 months,
this was 68.0% lower than that in those receiving no
treatment (Po0.05).
Measurement of 24-h albumin excretion showed sub-
stantial increases in both treated and untreated diabetic
groups by 4 months (Po0.05), which progressively increased
at 8 months (Po0.05). However, in NTU281-treated
animals, the increase in 24-h albumin excretion was lowered
by approximately 80% at the end point (Figure 2f),
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suggesting that TG inhibition slows down the deterioration
of glomerular structure and function.
Kidney scarring and morphology
After 1 month of hyperglycemia, there was no substantial
difference morphologically between the four experimental
groups (Figure 4a–d). By 4 months, kidney hypertrophy was
well established in the UNx, treated, and untreated
diabetic kidneys, with the largest increment occurring in
the diabetic groups (Figure 4e–h). Furthermore, in the
untreated diabetic kidney, both tubular atrophy and
peritubular fibrosis were noted (Figure 4g).
No evidence of interstitial fibrosis was seen at 8 months in
the normal (Figure 4i) and UNx (Figure 4j) kidneys. In
comparison, in the untreated diabetic kidney (Figure 4k),
there was extensive epithelial flattening, tubular atrophy, and
interstitial expansion with severe tubulointerstitial scarring.
Nearly all glomeruli showed advanced glomerulosclerosis,
with Bowman’s space filled with collagen. There was extensive
expansion of the mesangial matrix, the capillary network had
collapsed, and the glomeruli were extensively vacuolated. In
comparison, all these changes were dramatically reduced in
the NTU281-treated diabetic kidneys (Figure 4l), with only
mild focal tubular epithelial flattening and a minor expansion
of the tubular basement membrane.
Transmission electron microscopy of glomeruli in 8-month
kidneys showed significant widespread changes in both the
glomerular basement membrane (GBM) and the podocytes in
untreated diabetic kidneys (Figure 5a). There was a visible
thickening of the GBM and most noticeably an effacement/loss
of the podocytes, especially visible at a high power (Figure 5b).
Tg inhibition prevented the effacement/loss of podocytes,
whereas computerized morphometric assessment of GBM
thickness showed that the diabetic-induced GBM thickening
was prevented with TG inhibition (Figure 5c).
Quantification of kidney scarring
Computerized multiphase image analysis was used to assess
the degree of kidney scarring on Masson’s trichrome–stained
sections. Assessment of glomerulosclerosis (Figure 6a)
showed a significant increase in the level of fibrous tissue
present by 4 months post-hyperglycemia that progressed
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Figure 1 |NTU281 distribution. The kidney distribution of dansyl-labeled NTU281 (green) in both transverse and longitudinal planes from
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significantly by 8 months in untreated diabetic kidneys, being
fivefold that in control groups. NTU281-treated kidneys
showed no significant increase in glomerulosclerosis compared
with normal and UNx glomeruli over the 8-month period.
Tubulointerstitial fibrosis showed a similar trend to
glomerulosclerosis, with twofold increase in scarring at
4 months rising to sixfold by 8 months in untreated diabetic
animals (Figure 6b). NTU281 significantly reduced scarr-
ing in diabetic kidneys, with no detectable change compared
with control at 4 months and only a twofold increase by
8 months.
Kidney collagen content
Whole kidney collagen analysis was undertaken by measuring
hydroxyproline in hydrolyzed kidney homogenates. By
8 months post-STZ, the hydroxyproline constituted 0.89±
0.04% of total amino acids in untreated hyperglycemic
kidneys and double those in normal (0.42±0.03%) and UNx
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Figure 2 |Hyperglycemia, kidney function, and drug delivery. The volume of drug delivered per month was calculated from residual
volumes in the pump (a). Insulin implants required to control blood glucose to 10–25mmol/l were averaged for each experimental group
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creatinine concentration (mmol/l) (e). Twenty-four-hour albumin excretion (mg) was used to assess glomerular damage (f). White
circles¼ normal, black circles¼UNx, white squares¼ untreated DM, black squares¼NTU281-treated DM. Data represent mean±s.e.m.,
n¼ 4–7 per group. Significance (Po0.05) is indicated in comparison with normal (a), UNx (b), untreated DM (c), and NTU281-treated DM (d).
‘c’ Indicates statistical significance compared to the untreated diabetic group.
Table 1 | Final body weight and terminal kidney weight.
Time
Final body weight (g) Terminal kidney weight (g)
Groups 1 Month 4 Months 8 Months 1 Month 4 Months 8 Months
Normal 361±11.7 472±8.6 546±22.6 1.0±0.0 1.4±0.13 1.4±0.13
UNx 389±7.2a 447±14.2 514±15.8 1.4±0.08a 1.5±0.04 1.7±0.10
UNx+DM 319±13.4a,b 356±20.0a,b 355±12.8a,b 1.7±0.17a 3.1±0.30a,b 5.7±0.91a,b
UNx+DM+NTU281 320±6.7a,b 350±10.3a,b 377±14.3a,b 2.3±0.25a,b,c 2.8±0.36a,b 3.3±0.25a,b,c
Data represent mean±s.e.m., n=4–7 per group.
Significance (Po0.05) is indicated in comparison with normal (a), UNx (b), and untreated DM (c).
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animals (0.48±0.03%). In NTU281-treated diabetic kidneys,
hydroxyproline rose by just half that in the untreated
diabetics, reaching 0.67±0.03%.
Changes in collagen type I, III, and IV were investigated by
immunofluorescence. In early experimental DN (1 and 4
months), there was no significant change in either collagen I
(Figure 7a) or III (Figure 7b) staining in the kidney between
the four experimental groups. By 8 months, both collagen I
(Figure 7a) and collagen III (Figure 7b) were elevated in the
untreated diabetic kidney (Po0.05). Increased collagen I was
mainly found in sclerotic glomeruli (Figure 8c), whereas
elevated collagen III occurred in the expanded interstitium
and in periglomerular areas (Figure 8g). In contrast, levels
of both collagens in the NTU281-treated diabetic kidney
remained similar to those in normal. Collagen IV was
significantly increased by 4 months in the untreated diabetic
kidney (Po0.05) and continued to increase predominantly
in peritubular and periglomerular areas (Figure 8k) at
8 months (Po0.05). NTU281-treated diabetic kidneys had
collagen IV staining levels that were comparable with the
normal and UNx animals throughout experimental period
(Figure 7c).
Levels of kidney scarring significantly correlated with
changes in accumulation of collagen I (r¼ 0.515, Po0.01),
collagen III (r¼ 0.718, Po0.01), and collagen IV (r¼ 0.570,
Po0.01).
mRNA levels of collagen I, III, and IV
To detect if the TG inhibition had an effect on collagen
synthesis, northern blotting was performed using 4- and
8-month kidneys.
At 4 months, collagen I mRNA levels in the treated
diabetic kidney were similar to those in normal, but higher
than those in the UNx and untreated diabetic kidneys
(Figure 9a). By 8 months, collagen I mRNA levels in diabetic
kidneys were significantly higher than those in the normal
and UNx (Figure 9a) kidneys. The NTU281-treated kidney
had levels not significantly different from those in the
untreated diabetic kidney (Figure 9a).
The collagen III mRNA levels in the untreated diabetic
kidney reached fivefold higher than those in the normal
and UNx by 8 months (Figure 9b). In contrast, the levels in
the NTU281-treated kidney were normalized at this stage,
although they had been higher than those in the untreated
diabetic kidney at the earlier time point (Figure 9b).
The collagen IV mRNA levels in both treated and
untreated diabetic groups were similar and higher than those
in the UNx group at 4 months post-STZ administration
(Figure 9c). By 8 months, it was significantly increased in the
untreated diabetic kidney compared with that in the other
three experimental groups, with the levels more than double
those in normal (Figure 9c; Po0.05). Although the treated
group had levels higher than those in the normal, it was not
significant (Figure 9c).
Overall, the above results suggested that the TG inhibitor,
NTU281, had a minimal effect on collagen I mRNA levels,
but reduced the collagen III and IV mRNA levels by the end
of the study.
Myofibroblasts (a-smooth muscle actin-positive cells)
Less interstitial cells were observed on Masson’s trichrome-
stained sections in the TG inhibitor-treated kidney than
that in the untreated. ECM-producing myofibroblasts have
been reported to be associated with the progression of
fibrosis in DN.19,20 Therefore, the abundance of these
cells was determined using a-smooth muscle actin (SMA)
as a marker.
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Representative TG in situ activity confocal microscope images
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At 1 month, there were no substantial changes in a-SMA
staining between any of the experimental groups, although
significant increases in a-SMA staining were detected in
tubulointerstitial space of both treated and untreated diabetic
kidneys by 4 months (Figure 7d). This continued to increase
at 8 months (Figure 7d) in the untreated group (Figure 8o).
However, levels in the treated diabetic group were 67% lower
than those in the untreated diabetic kidney (Po0.05),
suggesting that TG inhibition reduced the accumulation of
myofibroblasts in advanced DN.
DISCUSSION
All current TG inhibitors block not only TG2 activity, but
also other TGs such as factor XIIIa, TG1, and TG3. Hence,
there is the potential for nonspecific effects that could
complicate data interpretation. For example, loss of kerati-
nocyte TG (TG1) activity has been reported to cause para-
keratosis and psoriasis-like symptoms when applied to skin
composites,21,22 whereas blocking factor XIIIa may poten-
tially lead to systemic effects such as hemorrhage and
bleeding. To overcome this, we employed NTU281, an
inhibitor designed to act on the outside of the cell,23 limiting
its targets to TG2 and factor XIIIa, which are the only two
forms of mammalian TG known to be secreted into the
extracellular space. Other potential targets such as cysteine
proteases are in the main intracellular in nature, whereas
concentrations up to 1mmol/l of NTU281 do not inhibit
other important cysteine-containing enzymes such as
caspase-3. In addition, osmotic minipumps were employed
to enable direct delivery of TG inhibitor into the kidney to
minimize dose and hence systemic effects. Pressures gener-
ated by these pumps ensure that blockage is unlikely, which is
supported by stable drug delivery volumes over the 8 months.
Application of dansyl-labeled NTU281 showed a uniform
distribution of the drug within the receiving kidney by this
method. Administration of 50mmol/l NTU281 from an
implantable osmotic pump at 2.5 ml/h to the remnant kidney
in the 5/6th nephrectomy (SNx) model has previously shown
to halt increases in kidney TG activity without affecting
blood clot stability or TG activity in other organs such as the
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heart, liver, and skin (unpublished data). Therefore, the same
dose of NTU281 was used in this study and proved equally
effective in reducing TG crosslinking activity in the diabetic
kidney throughout the study as shown by the reduction in
both TG in situ activity and crosslink levels, which were
uniform across the treated kidney.
TG inhibition resulted in preservation of kidney function
and a reduction in albuminuria as a consequence of lower
levels of both glomerulosclerosis and tubulointerstitial
fibrosis. On commencing this study, we expected that the
underlying mechanism would be related to changes in ECM
accumulation by blocking the post-translational processing
of the ECM by extracellular TG, given that in vitro studies
have repeatedly shown that TG2 alters ECM homeostasis by
accelerating the rate of collagen deposition12 and conferring
the ECM with resistance to MMP proteolysis.10 In keeping
with this, we see marked reductions in mature deposited
collagen I, III, and IV levels in the NTU281-treated diabetic
kidneys. The levels of collagen I mRNA remained high, with
levels between untreated and NTU281-treated groups
identical. In contrast, levels of collagen IV mRNA were
37% lower in the treated group and those of collagen III
mRNA similar to normal animals by 8 months The collagen
type I mRNA data clearly support a post-transcriptional
mechanism (as predicted) in the presence of a continual
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fibrotic stimuli for collagen I, but the additional, unantici-
pated, and interesting effect of NTU281 in suppressing type
III and IV collagen mRNA levels is suggestive of an additional
mechanism in lowering protein levels of these collagens.
This study was not designed to isolate particular
mechanisms, and it therefore remains unclear from the data
presented whether these improvements are a direct result of
TG inhibition or a secondary effect caused by the reduction
in fibrous tissue expansion (and thus fibrotic stimuli)
brought about by lowering TGase activity. However, one
could hypothesize as to two mechanisms that could lead to
lower levels of collagen III and IV mRNA. It has been
reported that TG2 is able to activate the fibrogenic cytokine
transforming growth factor-b1 (TGF-b1) by recruiting large
latent TGF-b1 in the ECM before proteolytic release of the
active dimer.24,25 Therefore, TG inhibition may affect
collagen synthesis by simply altering latent TGF-b1 activa-
tion, and this may be the case for collagen III and IV although
other in vivo (unpublished data) and in vitro15 studies using
TG inhibitors have failed to show lower active TGF-b1 levels.
Alternatively, tubular ischemia caused by ECM expansion
reducing blood flow to renal tubules may be less pronounced
following NTU281 treatment. The reduction in levels of
tubulointerstitial fibrosis in the treated diabetic kidney may
therefore allow a better perfusion of the tubular epithelium,
lowering the hypoxia-inducible factor-mediated induction of
ECM proteins.26
Apart from the reduction in ECM accumulation, another
marked effect of TG inhibition was the preservation of
tubulointerstitial architecture with less tubular atrophy and
interstitial myofibroblasts. Myofibroblasts undergo substan-
tial proliferation and synthesize high levels of ECM proteins
being central to the development of tubulointerstitial scarring
and fibrosis.27–29 Again, it remains unclear from our data
whether these improvements are a direct result of TG
inhibition or secondary to the reduction in ECM expansion.
TG inhibition was associated with a big improvement in
albuminuria indicating protection of glomerular structure.
Electron microscopy of glomeruli clearly showed that TG
inhibition was extremely effective in the preservation of
podocytes. Untreated animals had essentially no visible
podocytes on the GBM, indicating either loss or pedicel
retraction, whereas those receiving NTU281 had a podocyte
structure and number that was not discernable from both
control groups. The reason for this is most likely a
combination of qualitative changes to the GBM (such as
from the inclusion of collagen 1) and the 50% thicker GBM
shown by morphometric measurements.
Lower levels of interstitial a-SMA-positive cells in
NTU281-treated kidneys are suggestive of a reduction in
myofibroblast levels, although a-SMA is not specific for
myofibroblasts with smooth muscle cells in the vasculature,
being particularly evident in the kidney. Epithelial–
mesenchymal transdifferentiation is thought to be a major
contributor to interstitial fibrosis30,31 and thus a reduction in
this could account for lower a-SMA staining. As previously
mentioned, TG is known to have a role in latent TGF-b1
activation. Given TGF-b1 has been reported to be the most
potent inducer of tubular epithelial–mesenchymal transdif-
ferentiation,32 it could be hypothesized that the increased TG
activity in the diabetic kidney causes a rise in active TGF-b1
availability, resulting in the activation of myofibroblast. TG
inhibition may reduce the presence of myofibroblasts by
blocking TG-dependent TGF-b1-activation pathway.10,13,33
Of note was the variation in kidney TG activity in the
untreated diabetic in this model. Both control groups and the
NTU281-treated kidney showed no significant change in TG
activity over the 8 months. In contrast, the DM group had a
fourfold increase at 1 month, and returned to near normal at
4 months, with a threefold increase by 8 months. After
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Figure 7 |Quantification of collagen I, III, IV, and a-SMA
immunostaining. Kidney levels of collagen I (a), collagen III (b),
collagen IV (c), and a-SMA (d) staining (Figure 6) were assessed by
multiphase image analysis of 10 fields per section. White
circles¼ normal, black circles¼UNx, white squares¼ untreated
DM, black squares¼NTU281-treated DM. Data represent
mean±s.e.m., n¼ 4–7 per group. Significance (Po0.05) is
indicated in comparison with normal (a), UNx (b), untreated DM
(c), and NTU281-treated DM (d). a-SMA, a-smooth muscle actin.
‘c’ Indicates statistical significance compared to the untreated
diabetic group.
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repeating this assay several times, we believe that this genuinely
reflects the biphasic response of TG2. An early acute response
to hyperglycemia, which may predominantly reflect a synth-
esis-independent cell export of TG2 as described previously in
early DN,13 is followed by a late remodeling response that is
TG2 synthesis dependent as reported in aggressive fibrosis.10
The discrepancy between e-(g-glutamyl)lysine crosslink levels
and TG2 activity may seem contradictory, but is not
surprising. TG2 has a half-life of around 8 h and so is quickly
cleared, whereas the e-(g-glutamyl)lysine crosslink produced
by TG2 is very stable, requiring complete digestion of the
tissue to release it. Thus, if TG2 activity decreased, the
crosslink would remain high.
In conclusion, TG inhibition dramatically slows the deve-
lopment of experimental DN through a reduction in tubulo-
interstitial fibrosis and glomerulosclerosis. This preserves
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Figure 8 | Immunofluorescent staining of collagens I, III, IV, and a-SMA in kidneys 8 months post-hyperglycemia. Collagen I staining
(a–d) was performed on cryostat sections with collagen III (e–h), collagen IV (i–l), and a-SMA (m–p) on paraffin sections. Fields were acquired
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kidney function and slows the development of proteinuria.
The prime mechanism for this is most likely to be the
lowering of the direct action of TG on ECM crosslinking that
leads to matrix accumulation. The data suggest that TG
inhibitors offer a potential therapeutic avenue for the
amelioration of DN in the diabetic patient; however, clinical
application is likely to be dependent on the development of
isoform-specific compounds.
MATERIALS AND METHODS
Synthesis of TG inhibitor
NTU281 was synthesized according to published methods.15
Compound purity was determined by nuclear magnetic resonance
and mass spectrometry. Inhibitor efficacy was verified against renal
TGs by the application of the inhibitor at 100 and 500mmol/l to a
20% kidney homogenate, with activity measured using the [14C]
putrescine-incorporation assay.
Experimental animals and protocol
Male Wistar Han rats (Harlan, Bicester, UK) of 200–250 g and 8–10
weeks old were subjected to right uninephrectomy (UNx). Seven
days later, hyperglycemia was induced by a tail vein injection of STZ
(35mg/kg in citrate buffer, pH 4.0). Control animals were subjected
to either a sham operation or UNx with vehicle injection alone. An
early morning blood glucose level above 10mmol/l at 1 week after
STZ injection was considered diabetic. Blood glucose was controlled
between 10 and 25mmol/l using insulin implants (Research Pack;
LinShin, Toronto, Ontario, Canada). Practically, 1/4 insulin implant
was progressively inserted subcutaneously (using a trocar) until the
target glucose range was reached. Measurements were taken 48 h
after each 1/4 implant was inserted using a One Touch Basic glucose
meter (Johnson and Johnson, Langhorne, PA, USA). Blood glucose
measurements were repeated biweekly with replacement implants
inserted as required.
A 0.58-mm-bore polyethylene cannula was heat sealed at one
end and fenestrated between 2 and 12mm from the seal. The open
end was attached to a 2ML4 mini osmotic pump (Alzet, Cupertino,
CA, USA). At UNx, the cannula was passed longitudinally through
the remaining kidney such that all perforations were within the renal
parenchyma. The cannula was secured using silk ties and tissue glue
and run through the muscle wall to the pump located on the scruff.
Pumps were loaded with either phosphate-buffered saline (vehicle)
or 50mmol/l solution of NTU281 and replaced every 28 days when
exhausted.
Rats (1–4) were housed 4 to a cage at 20–221C and 45% humidity
on a 12-h light/dark cycle. They were allowed free access to standard
rat chow (Labsure Ltd, Cambridge, UK) and tap water. Animals
were divided into four groups: normal, uninephrectomy (UNx),
diabetes with UNx (UNxþDM), and diabetes with UNx treated
with NTU281 (UNxþDMþNTU281). At 1, 4, and 8 months after
STZ injection, rats were killed and kidneys removed from both
diabetic groups (nX6) and control groups (n¼ 4). Serum creatinine
was measured by standard autoanalyzer technique and 24 h
albuminuria by using the Bethyl Laboratories rat albumin ELISA
kit (BioGnosis, Hailsham, UK) following the manufacturer’s
instructions. All procedures were carried out under license
according to regulations laid down by Her Majesty’s Government,
United Kingdom (Animals Scientific Procedures Act, 1986).
NTU281 distribution
To ensure adequate distribution throughout the kidney, NTU281
was synthesized with a dansyl label. Animals cannulated as above
were infused with phosphate-buffered saline for 1 month for the
maximum fibrous coat to develop around the cannula (Figure 1a) at
which stage kidneys were infused with 50mM dansyl-NTU281 for
24 h as above. Kidneys were removed and halved longitudinally
along the cannula. Cryosections were cut at 10 mm and dansyl
visualized under a fluorescein isothiocyanate filter on a fluorescent
microscope using the contralateral kidney as a control. Analysis 3.2
image analysis software (Soft imaging Systems, Mu¨nster, Germany)
was used to generate full-length and width images using multifield
alignment. These were imported into Multi Analyst (Biorad, Hemel
Hempstead, UK) and a densitometric profile was generated.
Detection of in situ TG activity
Cryostat sections were incubated with 0.5mmol/l biotin cadaverine
(Molecular Probes, Breda, Netherlands) and 5mmol/l CaCl2. A
negative control in which CaCl2 was replaced with 10mmol/l EDTA
was used. Incorporated biotin cadaverine was revealed by immu-
noprobing with a streptavidin indodicarbocyanine (Cy5) conjugate
(Jackson ImmunoResearch, West Grove, PA, USA) at 1 in 50
dilution. Sections were visualized using a Leica TCS NT confocal
microscope (Leica DMRBE; Lasertechnik, Wetzlar, Germany) using
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Figure 9 |Northern blot analysis of collagen I, III, and IV
mRNA. mRNA levels of collagen I (a), collagen III (b), and collagen
IV (c) were assessed by northern blot analysis using volume
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a Kr/Ar laser (647 and 488 nm) for both Cy5 (optimal excitation
650 nm) and autofluorescence. Computer imaging was obtained at
665 and 530 nm for Cy5 and autofluorescence, respectively (Leica
TCS NT; Lasertechnik). Multiphase image analysis (Analysis 3.2;
Soft Imaging Systems) was performed to assess levels of incorpo-
rated cadaverine by dividing the area of red cadaverine stain with the
green tissue autofluorescence to correct for tissue mass.
Detection of e-(c-glutamyl)lysine crosslink
The determination of e-(g-glutamyl)lysine crosslink was similar to
that previously described.13 Cryostat sections were incubated with a
mouse monoclonal anti-e-(g-glutamyl)lysine isopeptide antibody
(81-D4; Covalab, Lyon, France) or mouse nonimmune serum
(DAKO, Ely, UK) at 1 in 20 dilution. After washing and fixing,
primary antibody was revealed using a donkey anti-mouse Cy5-
conjugated antibody (Jackson ImmunoResearch). Section visualiza-
tion and multiphase image analysis were performed as described
above.
Fibrosis measurement
Four-micrometer, neutral-buffered, formalin-fixed, paraffin-
embedded sections were stained with Masson’s trichrome (stains:
collagenous material blue; nuclei, fiber, erythrocytes and elastin, red/
pink). For glomerulosclerosis and tubulointerstitial scarring, 20
glomeruli ( 400) and 10 fields ( 200) of cortex tubules were
acquired respectively in a systematic manner. A fibrous coat can
develop around the renal cannula that can extend up to 1mm in
thickness (Figure 1, Masson’s trichrome insert). In sections
immediately above or below the cannula path, affected fields are
excluded from analysis to avoid data contamination. Fibrosis was
assessed using multiphase image analysis.34 The fibrosis index was
determined by dividing the area of blue collagenous stain by red
cellular stain, thus correcting for cell number.
Immunofluorescent measurements
Immunofluorescent staining was carried out on 4-mm paraffin
sections using a secondary antibody conjugated with fluorescein
isothiocyanate (DAKO). Following antigen retrieval, primary
antibodies were applied as follows: goat anti-collagen (a1) III
(1:10; Southern Biotech, Birmingham, AL, USA), rabbit anti-
collagen IV (1:35; ICN, Costa Mesa, CA, USA), and mouse anti-a-
SMA (1:100; DAKO). Collagen I immunofluorescence was per-
formed on 10-mm cryostat sections using a mouse anti-collagen
(a1) I antibody (1:50; Abcam, Cambridge, UK). Collagen IVantibodies
were not chain specific, recognizing a1, -2, -3, and -4 chains equally.
Ten cortical fields at  200 magnification of each section were
acquired. These were analyzed using multiphase image analysis as
above with correction to 4’,6-diamidino-2-phenylindole staining.
Electron microscopy
Tissue from paraffin blocks was recovered, post-fixed in gluter-
aldehyde, and subjected to transmission electron microscopy as
previously described35 using magnifications at  2600 and
 20,000. GBM thickness was determined by taking at least 10
GBM measurements per glomeruli for each animal at  20,000
magnification using Kodak AMTv600 image analysis software.
Measurement of mRNA levels
Total RNA was extracted using TRizol (Gibco, Paisley, UK) and
subjected to northern blot analysis as previously described.36
Autoradiographs were quantified by scanning densitometry using
a Biorad GS-690 densitometer and Molecular Analyst version 4
software. Densitometry values were corrected for loading using the
housekeeping gene cyclophilin.36
cDNA probes
Specific random primed DNA probes were constructed from the
following sequences: human collagen (a1) I,37 rat collagen (a1) III,38
and human collagen (a1) IV.39
Hydroxyproline analysis
Four hundred microliters of 10% kidney homogenates were
hydrolyzed in 6M HCl at 1101C for 18 h. These were clarified by
centrifugation at 14,000 r.p.m. for 2min and freeze-dried. This
was resuspended in 400 ml of lithium loading buffer and 20 ml
fractionated using a lithium chloride gradient on a Biochrom 30
amino acid analyzer as optimized by the manufacturer (Biochrom,
UK). Hydroxyproline was identified against an amino-acid standard
and expressed as a percentage of total amino acids.
Statistical analysis
Data analyses were performed using one-way analysis of variance
followed by a Bonferroni post hoc test. A probability of 95%
(Po0.05) was taken as significant. Correlation analysis was
performed on SPSS 12.0.1 for Windows.
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